schizophrenia

News and resources

Month: September 2025

Sep 18 2025

GLP-1: Promising Option to Counter Antipsychotic Weight Gain – Medscape

by Clinical Editor

No Comments

GLP-1: Promising Option to Counter Antipsychotic Weight Gain Medscape

Sep 18 2025

Antipsychotic-treated patients with schizophrenia see benefits from semaglutide, study claims

by Clinical Editor

No Comments

A multicenter collaboration of Danish researchers reports that once-weekly semaglutide for 30 weeks lowered blood sugar levels and body weight and improved physical quality of life in …

Sep 17 2025

Sex Differences May Affect Schizophrenia, Bipolar Outcomes – Medscape

by Clinical Editor

No Comments

Sex Differences May Affect Schizophrenia, Bipolar Outcomes Medscape

Sep 16 2025

Deep Learning Approach Shows Promise for Automatic Assessment of Schizophrenia Using Wearable Technology – Managed Healthcare Executive

by Clinical Editor

No Comments

Deep Learning Approach Shows Promise for Automatic Assessment of Schizophrenia Using Wearable Technology Managed Healthcare Executive

Sep 16 2025

Cat ownership mysteriously linked to this mental disorder, new study suggests – futura-sciences.com

by Clinical Editor

No Comments

Cat ownership mysteriously linked to this mental disorder, new study suggests futura-sciences.com

Sep 15 2025

Nonpharmacologic Treatment of Patients with Schizophrenia – Clinical Advisor

by Clinical Editor

No Comments

Nonpharmacologic Treatment of Patients with Schizophrenia Clinical Advisor

Sep 15 2025

Inside the Quest to Understand the Link Between Cannabis and Schizophrenia – Smithsonian Magazine

by Clinical Editor

No Comments

Inside the Quest to Understand the Link Between Cannabis and Schizophrenia Smithsonian Magazine

Sep 13 2025

LB Pharma prices $285M Nasdaq debut to help develop schizophrenia drug – Endpoints News

by Clinical Editor

No Comments

LB Pharma prices $285M Nasdaq debut to help develop schizophrenia drug Endpoints News

Sep 13 2025

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia – Yahoo Finance

by Clinical Editor

No Comments

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia Yahoo Finance

Sep 12 2025

FDA Approves Risperidone Extended-Release Injectable Suspension – Psychiatric Times

by Clinical Editor

No Comments

FDA Approves Risperidone Extended-Release Injectable Suspension Psychiatric Times